Table 1.
Baseline characteristics.
Fig 1.
PI-RADS v2.1 shows excellent performance in assessing DCE.
ROC-analysis of qualitative (DCE v2.1), semiquantative (DCE v1 and curve type), and quantitative (Ktrans, kep, ve) DCE parameters and multiparametric PI-RADS v1 and PI-RADS v2.1 for differentiation of prostate cancer and benign lesions in the peripheral zone (PZ, right) and transition zone (TZ, left). Areas under the curve (AUC) values are given in the bottom of each plot.
Fig 2.
Peripheral PCa lesion is declinable in most of the perfusion maps.
Example of a peripheral PCa lesion. Upper row: multiparametric MRI (from left to right with T2, DWI, ADC, and DCE showing a left peripheral carcinoma with gleason score 4+3 = 7 in a 48 year old patient. Lower row: corresponding perfusion maps (from left to right) colour-coded, Ktrans, kep, and ve.
Table 2.
Peripheral zone (PZ): Comparative analyses of qualitative (DCE v2.1), semiquantative (DCE v1 and curve type), and quantitative (Ktrans, kep, ve) DCE parameters and multiparametric PI-RADS v2.1 and PI-RADS v1 in PZ lesions with and without prostate carcinoma (PCa).
Table 3.
Transition zone (TZ): Comparative analyses of qualitative (DCE v2.1), semiquantative (DCE v1 and curve type), and quantitative (Ktrans, kep, ve) DCE parameters and multiparametric PI-RADS v2.1 and PI-RADS v1 in TZ lesions with and without prostate carcinoma (PCa).
Fig 3.
None of the other DCE methods can differentiate low grade tumor from clinicaly significant tumor alone.
ROC-analysis of qualitative (DCE v2.1), semiquantative (DCE v1 and curve type), and quantitative (Ktrans, kep, ve) DCE parameters and multiparametric PI-RADS v1 and PI-RADS v2.1 for differentiation of clinically significant carcinoma with Gleason score ≥7 vs. insignificant carcinoma with Gleason score <7 Areas under the curve (AUC) are given in the bottom right.
Table 4.
Comparative analyses of qualitative (DCE v2.1), semiquantative (DCE v1 and curve type), and quantitative (Ktrans, kep, ve) DCE parameters and multiparametric PI-RADS v2.1 and PI-RADS v1 in all lesions with prostate carcinoma (PCa) vs. benign (left) and all lesions with clinically significant carcinoma (csPCa) with Gleason Score ≥ 7 (ISUP Grade Group ≥ 2) vs. non-significant carcinoma (nsPCa) with Gleason Score 6 (ISUP Grade Group 1) (right).